These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 40028)

  • 1. Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
    Björkman S; Castensson S; Sievertsson H
    J Med Chem; 1979 Aug; 22(8):931-5. PubMed ID: 40028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MIF (Pro-Leu-Gly-NH2): failure to affect oxotremorine effects in mice and rats as well as fluphenazine catalepsy or amphetamine hyperactivity in rats.
    Björkman S; Lewander T; Zetterström T
    J Pharm Pharmacol; 1980 Apr; 32(4):296-7. PubMed ID: 6103063
    [No Abstract]   [Full Text] [Related]  

  • 3. On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use.
    Björkman S; Sievertsson H
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Jun; 298(2):79-81. PubMed ID: 18686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
    Björkman S; Castensson S; Lindeke B; Sievertsson H
    Acta Pharm Suec; 1976; 13(4):289-98. PubMed ID: 11638
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
    Voith K
    Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure activity relationship studies with hypothalamic peptide hormones III. Effect of melanotropin-release inhibiting factor and analogs on tolerance to morphine in the rat.
    Bhargava HN; Kim HS
    Neuropharmacology; 1982 Sep; 21(9):917-22. PubMed ID: 6128692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure activity relationship studies with hypothalamic peptide hormones. I. Effect of melanotropin release inhibiting factor and analogs on tolerance to morphine in the rat.
    Bhargava HN; Kim HS
    J Pharmacol Exp Ther; 1982 Feb; 220(2):394-8. PubMed ID: 6120229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of Pro-Leu-Gly-NH2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN.
    Johnson RL; Rajakumar G; Yu KL; Mishra RK
    J Med Chem; 1986 Oct; 29(10):2104-7. PubMed ID: 2876104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological activities of the MIF-1 analogues Pro-Leu-Gly, Tyr-Pro-Leu-Gly and pareptide.
    Mycroft FJ; Bhargava HN; Wei ET
    Peptides; 1987; 8(6):1051-5. PubMed ID: 2894644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute administration of MIF-1 or Tyr-MIF-1 inhibits haloperidol-induced catalepsy in rats.
    Hara C; Kastin AJ
    Pharmacol Biochem Behav; 1986 Jun; 24(6):1785-7. PubMed ID: 2874569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic MIF analogues. Part I: synthesis by four-component condensation (4 CC) and classical methods.
    Failli A; Sestanj K; Immer HU; Götz M
    Arzneimittelforschung; 1977; 27(12):2286-9. PubMed ID: 23794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-Leu-Gly-NH2 and pareptide inhibit development of tolerance to haloperidol catalepsy in the mouse.
    Mycroft FJ; Wei ET
    Peptides; 1984; 5(5):883-7. PubMed ID: 6150468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New evidence that demonstrates that L-pro-L-leu-L-gly-NH2 might be the natural MIF.
    Vivas A; Celis ME
    Acta Physiol Lat Am; 1977; 27(4):177-82. PubMed ID: 31762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Pro-Leu-Gly-NH2 (MIF) on the antinociceptive and thermoregulatory actions of morphine and oxotremorine.
    Slater P; Dickinson SL
    J Pharm Pharmacol; 1982 Feb; 34(2):113-5. PubMed ID: 6121869
    [No Abstract]   [Full Text] [Related]  

  • 15. Isolation of a novel peptide with a unique binding profile from human brain cortex: Tyr-K-MIF-1 (Tyr-Pro-Lys-Gly-NH2).
    Hackler L; Kastin AJ; Zadina JE
    Peptides; 1994; 15(6):945-50. PubMed ID: 7991457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and conformational study of two L-prolyl-L-leucyl-glycinamide analogues with a reduced peptide bond.
    Vander Elst P; Elseviers M; De Cock E; Van Marsenille M; Tourwé D; Van Binst G
    Int J Pept Protein Res; 1986 Jun; 27(6):633-42. PubMed ID: 2875969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and dopamine receptor modulating activity of unsubstituted and substituted triproline analogues of L-prolyl-L-leucyl-glycinamide (PLG).
    Baures PW; Pradhan A; Ojala WH; Gleason WB; Mishra RK; Johnson RL
    Bioorg Med Chem Lett; 1999 Aug; 9(16):2349-52. PubMed ID: 10476867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanocyte-stimulating hormone release-inhibiting factor-1 (MIF-1) can be formed from Tyr-MIF-1 in brain mitochondria but not in brain homogenate.
    Kastin AJ; Hahn K; Zadina JE; Banks WA; Hackler L
    J Neurochem; 1995 Apr; 64(4):1855-9. PubMed ID: 7891114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some observations on the pharmacological activity of MIF (Pro-Leu-Gly-NH2).
    Turnbull MJ; Wheeler H
    J Pharm Pharmacol; 1980 Nov; 32(11):803-4. PubMed ID: 6110739
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis and biological evaluation of analogues of Pro-Leu-Gly-NH2 modified at the leucyl residue.
    Johnson RL; Bontems RJ; Yang KE; Mishra RK
    J Med Chem; 1990 Jun; 33(6):1828-32. PubMed ID: 1971310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.